


Trimebutine

Cat. No.:	HY-B0380
CAS No.:	39133-31-8
Molecular Formula:	C ₂₂ H ₂₉ NO ₅
Molecular Weight:	387.47
Target:	Opioid Receptor
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (258.08 mM; Need ultrasonic)

Concentration	Mass			
	1 mg	5 mg	10 mg	
1 mM	2.5808 mL	12.9042 mL	25.8084 mL	
5 mM	0.5162 mL	2.5808 mL	5.1617 mL	
10 mM	0.2581 mL	1.2904 mL	2.5808 mL	

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Trimebutine is a drug with antimuscarinic and weak mu opioid agonist effects. Target: Opioid Receptor. Trimebutine is an agonist of peripheral mu, kappa and delta opiate receptors, used as spasmolytic agent for treatment of both acute and chronic abdominal pain [1]. The major product from drug metabolism of trimebutine in human beings is nor-trimebutine, which comes from removal of one of the methyl groups attached to nitrogen. Trimebutine exerts its effects in part due to causing a premature activation of phase III of the migrating motor complex in the digestive tract [2, 3].

REFERENCES

- [1]. Kaneto, H., M. Takahashi, and J. Watanabe, The opioid receptor selectivity for trimebutine in isolated tissues experiments and receptor binding studies. *J Pharmacobiodyn*, 1990. 13(7): p. 448-53.
- [2]. Roman, F.J., et al., Pharmacological properties of trimebutine and N-monodesmethyltrimebutine. *J Pharmacol Exp Ther*, 1999. 289(3): p. 1391-7.
- [3]. Hiyama, T., et al., Effectiveness of prokinetic agents against diseases external to the gastrointestinal tract. *J Gastroenterol Hepatol*, 2009. 24(4): p. 537-46.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA